NICE's severity modifiers misalign with public preferences in England & Wales, prioritising health gains at lower disease ...

This blog by Martina Garau (OHE) and Dr. Tina Wang (CIRS) provides a framework to navigate key aims, challenges and opportunities offered by recent initiatives and reflects on future prospects.

Ting (Tina) Wang is Associate Director, HTA Programme and Strategic Partnerships at the Centre for Innovation in Regulatory Science (CIRS). Tina leads CIRS’ work on HTA strategy and research as part ...

Stuart Carroll is a senior health economist and epidemiologist with over 18 years of experience, specialising in infectious diseases and vaccines, market access, health technology appraisal, public ...

Siva is chief analyst in the policy team, leading on projects covering NHS funding, finances, productivity and performance. Before joining the Fund in 2017, Siva was head of analysis at NHS Providers ...

Koonal is an associate director in the Science Policy and Research team at the National Institute for Health and Care Excellence. His project portfolio includes overseeing the NICE Listens ...

Donna is Professor of Health Economics at the School of Health and Related Research at the University of Sheffield.

Simon is a Health Economist and Electrical Engineer with over ten years of professional experience in international healthcare markets. His expertise covers the whole spectrum of health technologies, ...

Matthias is a Senior Economist at OHE and a Visiting Researcher at the Centre for Health Economics & Policy Innovation at Imperial College Business School. His expertise and research interests include ...

Hareth is a Professor of health economics at the Institute of Applied Health Research, University of Birmingham. He holds a Wellcome Trust Investigator Award (2020-2024) to research investments in ...